Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Lmcg Investments LLC

Key Points

• Lmcg Investments LLC significantly increased its holdings in Regeneron Pharmaceuticals by 132.0% during the second quarter, owning 33,597 shares worth approximately $17.6 million.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the last quarter, exceeding analyst expectations of $8.43 and showing a revenue increase of 3.6% year-over-year.
• The company declared a quarterly dividend of $0.88, representing an annualized rate of $3.52 with a yield of 0.6% and a payout ratio of 8.87%.

Lmcg Investments LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 132.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,597 shares of the biopharmaceutical company's stock after buying an additional 19,116 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 1.1% of Lmcg Investments LLC's investment portfolio, making the stock its 22nd largest holding. Lmcg Investments LLC's holdings in Regeneron Pharmaceuticals were worth $17,638,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after buying an additional 121,545 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Regeneron Pharmaceuticals by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after buying an additional 89,579 shares during the period. Amundi increased its holdings in Regeneron Pharmaceuticals by 3.4% in the 1st quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company's stock worth $979,794,000 after buying an additional 52,166 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after purchasing an additional 174,056 shares during the period. Finally, American Century Companies Inc. grew its stake in shares of Regeneron Pharmaceuticals by 2.1% during the 1st quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company's stock worth $458,211,000 after purchasing an additional 14,921 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $564.63 on Friday. The company's fifty day moving average price is $573.95 and its 200 day moving average price is $565.04. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,024.36. The stock has a market capitalization of $59.85 billion, a P/E ratio of 14.23, a P/E/G ratio of 1.82 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the company earned $11.56 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of analyst reports. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $817.46.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.